Eloxx Pharmaceuticals Inc(ELOX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 36.63% | Shs Outstand | 4.0M | Perf Week | 8.93% |
| Market Cap | 0.05B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 2.6M | Perf Month | -20.5% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | -0.58 | Inst Own | 42.87% | Short Float | 2.11% | Perf Quarter | 10.83% |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | 21.37% | Short Ratio | 1.24 | Perf Half Y | 830.07% |
| Sales | - | P/B | 1.16 | EPS next 5Y | - | ROA | - | Short Interest | 0.05M | Perf YTD | 1208990.93% |
| Book/sh | 11.5 | P/C | 0.87 | EPS past 3/5Y | 75.85% 61.6% | ROE | - | 52W High | -43.16% | Perf Year | 1208990.92% |
| Cash/sh | 15.35 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | - | Perf 3Y | -27.6% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 11.29% 9.98% | Perf 5Y | -97.9% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.52 | Perf 10Y | -99.06% |
| Dividend Ex-Date | - | Quick Ratio | 3.74 | EPS Q/Q | 96.93% | Profit Margin | - | RSI (14) | 42.3 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.74 | Sales Q/Q | - | SMA20 | -7.28% ($14.34) | Beta | - | Target Price | $38.25 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/12 | SMA50 | -17.27% ($16.08) | Rel Volume | 0.37 | Prev Close | $13.22 |
| Employees | 10 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | 78.43% ($7.45) | Avg Volume(3M) | 0.04M | Price | $13.3 |
| IPO | 1998/12/11 | Option/Short | No/Yes | Trades | 579 | Volume | 16,285 | Change | 0.61% |
🔬 A clinical-stage biopharmaceutical company developing novel small-molecule drug candidates for the treatment of rare and ultra-rare genetic diseases. The company is researching technology that modulates ribosomes and promotes the readthrough of premature stop codons caused by nonsense mutations.
Over the past 1 year, roughly in the middle
Traded less than usual. That is 37% of its average volume.
Holding long would have lost money
Bought 5 years ago, your return today would be -97.9%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 42.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VTI Vanguard Morningstar Total Stock Market ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #413 of 595 in the industry
Based on market cap of $54M.
INKT#411 MiNK Therapeutics Inc $54M PER - 
RNTX#412 Rein Therapeutics Inc $54M PER - ELOX#413 Eloxx Pharmaceuticals Inc $54M PER - 
CLNN#414 Clene Inc $53M PER - 
LONA#415 LeonaBio Inc $53M PER - 
